Kezar Life Sciences, Inc.
KZR
$6.24
$0.091.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -41.06% | -33.22% | -27.92% | -43.32% | -29.18% |
| Gross Profit | 41.06% | 24.83% | 19.56% | 38.28% | 22.18% |
| SG&A Expenses | -11.85% | -18.64% | -17.01% | -11.86% | -9.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 33.50% | -- | -- | -- | -- |
| Total Operating Expenses | -31.45% | -28.52% | -25.10% | -20.22% | -7.22% |
| Operating Income | 31.45% | 23.49% | 20.08% | 14.92% | 0.52% |
| Income Before Tax | 35.57% | 28.18% | 22.40% | 17.80% | -9.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.57% | 28.18% | 22.40% | 17.80% | -9.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.57% | 28.18% | 22.40% | 17.80% | -9.10% |
| EBIT | 31.45% | 23.49% | 20.08% | 14.92% | 0.52% |
| EBITDA | 31.72% | 23.69% | 20.25% | 15.05% | 0.55% |
| EPS Basic | 14.75% | 8.00% | 2.84% | -1.56% | -8.52% |
| Normalized Basic EPS | 7.29% | 0.21% | -1.94% | -6.59% | 0.18% |
| EPS Diluted | 14.75% | 8.00% | 2.84% | -1.56% | -8.52% |
| Normalized Diluted EPS | 7.29% | 0.21% | -1.94% | -6.59% | 0.18% |
| Average Basic Shares Outstanding | 0.36% | 0.37% | 0.41% | 0.48% | 0.57% |
| Average Diluted Shares Outstanding | 0.36% | 0.37% | 0.41% | 0.48% | 0.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |